person · Reporting owner
Sommadossi Jean-Pierre
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABG Acquisition Corp. IABGI · Entity 115963 | Director | March 01, 2023 | March 03, 2023 |
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director · President, CEO, and Chairman | January 31, 2026 | February 03, 2026 |
| Kezar Life Sciences, Inc.KZR · Entity 12111 | Director | June 28, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABG Acquisition Corp. I
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 32,500 · Balance 0 F1: The Class B ordinary shares ("Class B Shares") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date. F2: This Form 4 reflects the surrender to the Issuer of 32,500 Class B Shares for no consideration by the Reporting Person pursuant to the Share Surrender Letter, dated March 1, 2023, by and between the Issuer and the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares ("Class B Shares") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date.
F2: This Form 4 reflects the surrender to the Issuer of 32,500 Class B Shares for no consideration by the Reporting Person pursuant to the Share Surrender Letter, dated March 1, 2023, by and between the Issuer and the Reporting Person.
Atea Pharmaceuticals, Inc.
Report date January 31, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 767,830 |
Ending reported balance
After 2026-02-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-31 · Exercise / conversion · Acquired 272,983 · Balance 573,923 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-01-31 · Tax withholding · Disposed 106,093 · Balance 467,830 Row 3 · 2026-02-03 · Exercise / conversion · Acquired 300,000 · Balance 767,830 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-31 · Exercise / conversion · Disposed 173,466 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-31 · Exercise / conversion · Disposed 99,517 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026. F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2026-12-08 | Direct | 0 |
Reported balance
After 2026-02-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-03 · Exercise / conversion · Disposed 300,000 · Balance 0 F5: The option is fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectHeld by JPM Partners LLC | 5,866,025 |
Reported balance
Holding disclosure · report date 2026-01-31 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,866,025 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4: Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.
F5: The option is fully vested and exercisable.
Kezar Life Sciences, Inc.
Report date June 28, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.59 · Expires 2031-06-27 | Direct | 26,000 |
Reported balance
After 2021-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-28 · Grant · Acquired 26,000 · Balance 26,000 F1: One-hundred percent (100%) of the shares subject to the option shall vest on 6/28/2022, subject to Reporting Person continuing to provide service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-hundred percent (100%) of the shares subject to the option shall vest on 6/28/2022, subject to Reporting Person continuing to provide service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · derivative · entry 7 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2026-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 03, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 300,000 | $1.24 | $372,000.00 |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · nonDerivative · entry 3 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 99,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · derivative · entry 6 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · shares: Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026. F3 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. F3 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026. F4 · derivative.underlying_shares: Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 173,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · derivative · entry 5 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. F2 · derivative.expiration_date: The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 106,093 | $4.24 | $449,834.32 |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · nonDerivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,830 Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 19:46 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 272,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-036268 · ownership.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 573,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · derivative · entry 7 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2035-01-30 F5 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2025 such that the option is fully vested on January 31, 2029. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 99,518 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · derivative · entry 6 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,518 Underlying: Common Stock · 99,518 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. F4 · derivative.expiration_date: Reflects RSUs following the satisfaction of performance criteria of previously granted PSUs. The RSUs will vest on January 31, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 173,467 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · derivative · entry 5 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,466 Underlying: Common Stock · 173,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Tax withholdingCommon Stock | 88,601 | $3.06 | $271,119.06 |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · nonDerivative · entry 3 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,940 Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantCommon Stock | 99,517 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · nonDerivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,541 F2 · price: Reflects shares received upon the satisfaction of performance criteria and time-vesting requirements associated with previously granted performance restricted stock units ("PSUs"). Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 18:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 173,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-013846 · ownership.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| September 19, 2024 Filed Sep 19, 2024 20:02 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 1,841 | $4.00 | $7,367.50 |
DisclosureSEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 3 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 5,866,025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.01. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 20:02 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 22,187 | $4.03 | $89,469.08 |
DisclosureSEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 5,867,866 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.0975. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 20:02 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 33,941 | $4.05 | $137,318.50 |
DisclosureSEC source: 0000950170-24-108233 · ownership.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 5,890,053 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.00 to $4.14. The Reporting Person undertakes to provide Atea Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 18:34 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 1,006 | $4.00 | $4,024.00 |
DisclosureSEC source: 0000950170-24-070965 · ownership.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 5,923,994 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | SaleCommon Stock | 56,910 | $3.85 | $218,818.95 |
DisclosureSEC source: 0000950170-24-010972 · ownership.xml · nonDerivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,557 F2 · shares: Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated May 18, 2023. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 448,000 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000950170-24-010972 · ownership.xml · derivative · entry 5 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448,000 Underlying: Common Stock · 448,000 shares Expires 2034-01-30 F4 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 173,467 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-010972 · ownership.xml · derivative · entry 4 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 346,933 Underlying: Common Stock · 173,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. F3 · derivative.expiration_date: The original grant of 520,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:30 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 173,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-010972 · ownership.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:00 UTC | ABG Acquisition Corp. I ABGI · Entity 115963 | Disposition to issuerClass B ordinary shares · Derivative | 32,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-006943 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 32,500 shares Expires not disclosed F1 · derivative.exercise_price: The Class B ordinary shares ("Class B Shares") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date. F2 · price: This Form 4 reflects the surrender to the Issuer of 32,500 Class B Shares for no consideration by the Reporting Person pursuant to the Share Surrender Letter, dated March 1, 2023, by and between the Issuer and the Reporting Person. F1 · derivative.exercise_date: The Class B ordinary shares ("Class B Shares") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date. F1 · derivative.expiration_date: The Class B ordinary shares ("Class B Shares") would have automatically converted into Class A ordinary shares of the Issuer at the time of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, with no expiration date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:33 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 728,600 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-23-003615 · doc4.xml · derivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 728,600 Underlying: Common Stock · 728,600 shares Expires 2033-01-30 F3 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:33 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 520,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003615 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,400 Underlying: Common Stock · 520,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. F2 · derivative.expiration_date: The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 17:15 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 378,033 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0000899243-22-004182 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,033 Underlying: Common Stock · 378,033 shares Expires 2032-01-30 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2022. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 18:49 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-21-044091 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2031-06-27 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/28/2022, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| January 29, 2021 Filed Feb 1, 2021 16:56 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 640,000 | $0.00 Strike: $73.00 | $0.00 |
DisclosureSEC source: 0000899243-21-003873 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,000 Underlying: Common Stock · 640,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 29, 2021. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 20:08 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionSeries A Convertible Preferred Stock · Derivative | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030329 · doc4.xml · derivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 0 Underlying: Common Stock · 750,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| November 03, 2020 Filed Nov 3, 2020 20:08 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | ConversionCommon Stock | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-030329 · doc4.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director · President, CEO, and Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Held by JPM Partners LLC Disclosed balance after: 5,925,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 17:09 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 8,896 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-20-039113 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2030-06-23 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/24/2021, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 18:54 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | GrantStock Option (Right to Buy) · Derivative | 8,896 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001209191-19-039356 · doc4.xml · derivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,896 Underlying: Common Stock · 8,896 shares Expires 2029-06-24 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option shall vest on 6/25/2020, subject to Reporting Person continuing to provide service through such date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:54 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries B Convertible Perferred Stock · Derivative | 35,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039678 · doc4.xml · derivative · entry 4 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JPM Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 35,258 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:54 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionSeries A Convertible Perferred Stock · Derivative | 52,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039678 · doc4.xml · derivative · entry 3 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JPM Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 52,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:54 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 35,258 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039678 · doc4.xml · nonDerivative · entry 2 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JPM Partners, LLC Disclosed balance after: 178,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:54 UTC | Kezar Life Sciences, Inc. KZR · Entity 12111 | ConversionCommon Stock | 52,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-039678 · doc4.xml · nonDerivative · entry 1 Sommadossi Jean-Pierre · CIK 0001296995 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JPM Partners, LLC Disclosed balance after: 143,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.